Sign inJoin waitlistJoin the waitlist

BA

Bertrand Anz

Physician · OneOncology

Credentials: · · · · · ·

History

OneOncology
Present

Wake Forest Baptist Hospital
2007–2010
Wake Forest Baptist Hospital
2004–2007
University of South Alabama College of Medicine
2000–2004

Research

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label,…
The Lancet Oncology · 2019 · 481 citations
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE…
Haematologica · 2022 · 119 citations
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes
Cancer · 2017 · 90 citations

IF
Ian Flinn
6 papers
JB
Jesus Berdeja
4 papers
LS
Lori Styles
3 papers
AA
Amit Agarwal
2 papers
CZ
Cathy Zhou
2 papers · 2 as a resident
Christopher Seet
2 papers
Christy Samaras
2 papers
David Siegel
2 papers
David Wright
2 papers
DQ
Donald Quick
2 papers
Gary Schiller
2 papers
Gustavo Fonseca
2 papers

Clinical trials

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Site PI · Recruiting · Phase 3
Loxo Oncology, Inc.
2022–2028